RxDoctor Payments DataLook up a doctor →

Eric Dippel, MD

Interventional Cardiology · Davenport, IANPI 1083693949

Payments from drug & device makers

$121,330in general payments, 2019–2025

Across 319 payments — averaging $380.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$48K
  • Asahi Intecc USA, Inc.$20K
  • M.a. Med Alliance S.A.$19K
  • Abbott$9K
  • Asahi Intecc CO., LTD.$7K
  • Medtronic$5K
  • plus $14K from 28 others
$4,500in research payments, 2019–2025

Across 2 payments — averaging $2250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Veryan Medical Incorporated$4K
  • Asahi Intecc USA, Inc.$1K

What the payments were for

  • Consulting fees$20,26020%
  • Speaking & faculty fees$29,04629%
  • Travel & lodging$38,88139%
  • Food & beverage$12,13112%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,330 in reported general payments places this provider in the 85th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$1,156,425
Medicare patients
441
Services billed
15,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cilostazol28$1,048
ClopidogrelClopidogrel Bisulfate33$162

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →